CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- SC 13G/A Stake Amended Statement of Ownership
- 4/A Derivatives Options or other derivatives
- 4 Grant or award Senior Vice President, R&D acquired 15,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 15,000 shares (grant or award)
- 4 Grant or award SVP, GC & Corporate Secretary acquired 15,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 15,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 15,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 57,260 shares (grant or award)
- 8-K Event Results of operations
- 4 Open-market sale SVP, GC & Corporate Secretary sold 1,376 shares at an average $26.83 ($36,918)
- 4 Open-market sale Chief Executive Officer sold 6,876 shares at an average $26.83 ($184,483)
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market sale Director sold 5,549 shares at $26.02 ($144,385)
- 4 Open-market sale Director sold 7,891 shares at $23.43 ($184,849)
- 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $23.29 ($174,675)
- 8-K Event Acquisition or sale completed
- 8-K/A Event Other events
- 4 Open-market sale Chief Financial Officer sold 7,500 shares at $23.98 ($179,813)
- 4 Open-market sale Senior Vice President, R&D sold 2,500 shares at $23.96 ($59,900)
- 4 Open-market sale SVP, GC & Corporate Secretary sold 2,500 shares at $23.98 ($59,950)
Page 33 of 65 · 1,286 filings